NEW YORK ( TheStreet) -- Savient Pharmaceuticals (Nasdaq: SVNT) hit a new 52-week low Monday as it is currently trading at $2.26, below its previous 52-week low of $2.27 with 1.5 million shares traded as of 2:56 p.m. ET. Average volume has been 1.7 million shares over the past 30 days. Savient has a market cap of $168 million and is part of the health care sector and drugs industry. Shares are down 79.4% year to date as of the close of trading on Friday. Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company in the United States. It engages in developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients refractory to conventional therapy.
TheStreet Ratings rates Savient as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, generally disappointing historical performance in the stock itself and generally weak debt management. You can view the full Savient Ratings Report. See all 52-week low stocks or get investment ideas from our investment research center.